Paracetamol como coadyuvante a opioides fuertes en dolor oncológico moderado a intenso: ¿es realmente efectivo?
- Autores: Ofelia Leiva, Pedro Pérez-Cruz
- Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 149, Nº. 6, 2021, págs. 899-905
- Idioma: español
- Títulos paralelos:
- Paracetamol as an adjuvant to opioids for cancer pain management
- Enlaces
-
Resumen
Cancer related pain is one of the most frequent and relevant symptoms in patients with malignant tumors, causing a huge impact in their quality of life. According to the Chilean Public Health System Technical Report of the Cancer Pain Control and Palliative Care Program 2013-2014, 90% of cancer patients admitted to the Program experienced pain, being moderate or intense in 34%. International and local standards recommend the use of strong opioids (morphine, methadone, or fentanyl) associated with adjuvants such as paracetamol as an initial strategy for pain management. This recommendation assumes that the use of combined analgesics could allow the use of lower opioid doses to obtain similar analgesic effect, decreasing the occurrence of opioid side effects. However, this technical report also describes that there is uncertainty about the impact of paracetamol as an adjuvant in patients with cancer pain who are already receiving strong opioids. This review aims to describe the current state of the art regarding the role of paracetamol as a coadjuvant in cancer pain patients.
